Search for: "Tom Lamb" Results 1 - 20 of 1,048
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Jul 2024, 12:53 pm by Tom Lamb
Growing Number of Pulmonary Embolism and DVT Cases Involving Semaglutide Reported by Patients   (Posted by Tom Lamb at Drug Injury Watch)   Wegovy, Rybelsus, and Ozempic have been associated with an increased risk of blood clots that can lead to pulmonary embolism (sometimes called PE) and deep vein thrombosis (often called DVT). [read post]
5 Jul 2024, 9:30 am by Tom Lamb
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), or "Eye Stroke", Can Cause Vision Loss   (Posted by Tom Lamb at Drug Injury Watch)   Wegovy, Rybelsus, and Ozempic eye side effects are possible given the recent finding that the active ingredient of these three drugs semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION). [read post]
28 Jun 2024, 11:45 am by Tom Lamb
EMA’s CHMP Does Not Approve Syfovre for a Second Time, Citing "significant risk of adverse events"   (Posted by Tom Lamb at Drug Injury Watch)   There seems to be some disagreement about the Syfovre safety-benefit assessment when it comes to the US FDA and its European counterpart, the European Medicines Agency (EMA). [read post]
14 May 2024, 2:07 pm by Tom Lamb
Semaglutide-related Side Effects Include Ischemic Stroke, Pulmonary Embolism, and Deep Vein Thrombosis   (Posted by Tom Lamb at Drug Injury Watch)   Wegovy, Rybelsus, and Ozempic are drugs with semaglutide as their active ingredient. [read post]
24 Apr 2024, 11:30 am by Tom Lamb
She Went to the Local ER With Loss of Vision 11 Days After Receiving an Intravitreal Syfovre (Pegcetacoplan) Injection   (Posted by Tom Lamb at Drug Injury Watch)   In the March 2024 edition of the American Journal of Ophthalmology Case Reports medical journal, there is a Syfovre retinal vaso-occlusive vasculitis case report involving a 78-year old woman with vision loss that happened back in the first part of 2023. [read post]
24 Apr 2024, 5:57 am by Norman L. Eisen
This autocracy threat tracker is also available as a PDF file. [read post]
4 Apr 2024, 11:52 am by Tom Lamb
Retinal Vasculitis After Syfovre Injections: Etiology is Still Unknown and Incidence Rate Remains Unclear   (Posted by Tom Lamb at Drug Injury Watch)   Syfovre (pegcetacoplan) was approved by the FDA in February 2023 as an eye injection to treat geographic atrophy (GA), a relatively rare condition secondary to age-related macular degeneration. [read post]
8 Mar 2024, 3:00 am by Jim Sedor
National/Federal Nikki Haley Suspends Her Campaign and Leaves Donald Trump as the Last Major Republican Candidate Associated Press News – Steve Peoples and Meg Kinnard | Published: 3/6/2024 Nikki Haley suspended her presidential campaign after being soundly defeated across the country on Super Tuesday, leaving Donald Trump as the last remaining major candidate for the 2024 Republican nomination. [read post]
6 Mar 2024, 12:10 pm by Tom Lamb
Pre-Existing Allergy Toward Polyethylene Glycol (PEG) is Most Recent Causation Theory Offered by Apellis   (Posted by Tom Lamb at Drug Injury Watch)   In late January 2024, a leading medical journal for ophthalmologists and retina specialists, the Journal of VitreoRetinal Diseases, published this Syfovre case report, "Occlusive Retinal Vasculitis After a Single Injection of Pegcetacoplan", written by three authors affiliated with the Department of… [read post]
22 Feb 2024, 10:10 am by Tom Lamb
Research Finding: Semaglutide Increased the Risk of Deep Vein Thrombosis (DVT) by 266% in Patients with Type 2 Diabetes   (Posted by Tom Lamb at Drug Injury Watch)   Semaglutide-containing drugs that are being used for weight loss purposes include Ozempic, Rybelsus, and Wegovy. [read post]
9 Feb 2024, 12:03 pm by Tom Lamb
Learn About Related Symptoms and Diagnosis Process for Gastroparesis, a Side Effect of Ozempic, Wegovy, Rybelsus, and Trulicity   (Posted by Tom Lamb at Drug Injury Watch)   In this article, we present some gastroparesis case reports involving the use of GLP-1 receptor agonists semaglutide (e.g., Ozempic, Wegovy, Rybelsus) or dulaglutide (e.g., Trulicity) that have been published recently by medical journals. [read post]
19 Jan 2024, 12:48 pm by Tom Lamb
Prolia "Black Box" Warning: Harm From Severe Hypocalcemia Ranges From Hospitalization For Life-threatening Events To Death   (Posted by Tom Lamb at Drug Injury Watch)   A January 2024 JAMA Original Investigation article, "Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients", in summary, presents evidence of a Prolia increased risk of hypocalcemia in patients with chronic kidney disease (CKD) that can be… [read post]
27 Dec 2023, 1:15 pm by Tom Lamb
December 2023 JAMA Ophthalmology Viewpoint Piece About Syfovre Calls for Independent and Unbiased Evaluation   (Posted by Tom Lamb at Drug Injury Watch)   Since the February 2023 FDA approval of Syfovre (pegcetacoplan), Apellis Pharmaceuticals has had to contend with various Syfovre safety issues related to its eye injection treatment for geographic atrophy. [read post]
4 Dec 2023, 2:01 pm by Tom Lamb
November 2023 Syfovre Label Change Comes After Earlier Reports of Eye Inflammation and Severe Vision Loss   (Posted by Tom Lamb at Drug Injury Watch)   We have been writing about Syfovre drug safety developments having to do with retinal vasculitis cases and other eye-related side effects since July 2023. [read post]
10 Nov 2023, 2:55 pm by Tom Lamb
A Syfovre Case of Hemorrhagic Occlusive Vasculitis-type Inflammation With Continued Blindness Is Reported   (Posted by Tom Lamb at Drug Injury Watch)   At the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO), various Syfovre patients eye side effects cases were discussed by William J. [read post]
30 Oct 2023, 8:51 am by jonathanturley
Here is my annual list of Halloween torts and crimes. [read post]
24 Oct 2023, 3:20 pm by Tom Lamb
Researchers Compared Semaglutide Drugs, Such as Ozempic and Wegovy, to Contrave, a Non-GLP-1 Drug, in Weight-Loss Patients   (Posted by Tom Lamb at Drug Injury Watch)   An October 2023 medical journal article presented the results of a recent study comparing patients who used two different types of weight-loss drugs to see whether drugs containing the GLP-1 semaglutide showed Ozempic and Wegovy associated with gastroparesis, a gastrointestinal condition… [read post]
13 Oct 2023, 3:20 pm by Tom Lamb
On That Aspect, in August 2023 Apellis Asked Doctors to Stop Using Syfovre Injection Kits With a 19-gauge Filter Needle   (Posted by Tom Lamb at Drug Injury Watch)   On October 5, 2023, Apellis Pharmaceuticals issued an update for its Syfovre investigation into retinal vasculitis cases involving patients who used Syfovre for geographic atrophy (GA). [read post]
28 Sep 2023, 12:40 pm by Tom Lamb
Paralytic Ileus, the Slowing of Food Movement Through Digestive System, is Similar to Intestinal Obstruction   (Posted by Tom Lamb at Drug Injury Watch)   In September 2023 the Ozempic (semaglutide) drug label was updated to inform doctors and patients that adverse reaction reports concerning ileus, a gastrointestinal disorder, have been received for semaglutide during the time since Ozempic was first approved by the FDA in 2017. [read post]
13 Sep 2023, 1:15 pm by Tom Lamb
Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis   (Posted by Tom Lamb at Drug Injury Watch)   Semaglutide is the active ingredient in three Novo Nordisk drugs that are being used for weight loss purposes: Ozempic, which was approved in 2017 by the FDA as a Type 2 diabetes treatment, such that Ozempic is being used "off-label" for weight loss; Rybelsus, approved in 2019 as Type 2 diabetes treatment,… [read post]